Introduction
Bacteremia is clinically seen in febrile neutropenic patients with hematological malignancies. In particular, Gram-negative organisms are renowned for inducing septic shock, which is often followed by sepsis-related death. Several groups have reported that the prevalence of Gram-negative bacteremia has increased among episodes of febrile neutropenia in hemato-oncology units. 1, 2 A prompt initiation of empirical antibiotic therapy is favorable for patients with febrile neutropenia, regardless of the detection of bacteremia. Many clinical studies have recommended broadspectrum antibiotics covering both Gram-positive and-negative bacteria as first-line treatment for febrile neutropenic patients. Certain specific agents have been used worldwide, including thirdand fourth-generation cephalosporins, carbapenems, and blactam/b-lactamase inhibitor combinations. In recent years, monotherapy using these antibiotic agents has been shown to be comparable to combination therapy with regard to the efficacy of treatment of febrile neutropenia. [3] [4] [5] [6] Based on these studies and guidelines, 7, 8 our unit adopted the single administration of cefepime, a fourth-generation cephalosporin, as the initial treatment for febrile episodes in neutropenic patients.
It is now unquestioned that the use of broad-spectrum antimicrobial agents renders many clinically important organisms highly resistant to various antibiotics. In the general population, extended-spectrum b-lactamase (ESBL)-producing Gram-negative bacteria have been reported to be increasing in prevalence among all bacteria detected, and an increase in the use of cephalosporins may be related to the emergence of ESBL-producing bacteria. 9, 10 In febrile neutropenic patients with hematological malignancies, the relatively recent resistance pattern of Gram-negative bacteremia appears inconclusive. Commonly used agents, such as cefepime and carbapenems, have shown high activity against Gram-negative bacteremia detected in neutropenic patients, 11 while other studies have reported the occurrence of Gram-negative bacteremia resistant to many antibiotics. [12] [13] [14] The susceptibility pattern of organisms isolated from one region may not be the same as that found in other regions of the world, as various environmental factors affect the acquisition of antibiotic resistance. However, constant surveillance and reporting are needed regarding antibiotic susceptibility. This is particularly important in the field of febrile neutropenic bacteremia, because the emergence of isolates resistant to critical antibiotics limits antibiotic choices and may lead to an increase in infection-related mortality. In this study, 142 blood culture isolates recovered from febrile neutropenic patients treated in a single hematological unit were analyzed with regard to etiology and susceptibility to antibiotics. Cefepime resistance was seen in 24 (35.3%) of 68 Gram-negative isolates. Approximately 60% of the cefepime-resistant isolates were ESBL-producing Escherichia coli and Klebsiella pneumoniae. Moreover, molecular characterization of ESBL-producing isolates showed a predominance of the CTX-M-type, which is currently emerging worldwide. Although these results were obtained from a single institution, they contain important information that implies the necessity of modifying antibiotic strategies for febrile neutropenia.
Methods

Patients
A total of 872 patients were admitted to the blood and marrow transplantation unit at Hara-Sanshin Hospital from January 2006 to December 2008. Bacteremia in febrile neutropenic patients was analyzed in the present study for two reasons: (1) the number of Gram-negative strains isolated up to the year 2005 was very small, and (2) some of the patients admitted up until 2005 had received prophylactic administration of antibiotics during neutropenic periods. The prophylactic use of antibiotics is known to affect the etiology of febrile neutropenic bacteremia. 15 Neutropenic patients admitted after January 2006 had only taken antimycotic agents for prophylaxis. All the patients with febrile neutropenia were registered and their informed consent for study participation was obtained. Febrile neutropenia was defined as a neutrophil count of < 0.5 Â 10 9 cells/l and an axillary temperature of > 38.0 8C.
Cefepime, a fourth-generation cephalosporin, has been adopted as an initial empirical antibiotic agent for febrile neutropenic patients. Cefepime at a dosage of 4 g/day was used, and during the study period the defined daily dose per 1000-patient days of cefepime was 171. The administration of antibiotics was continued until recovery of neutrophil counts and/or resolution of infection. When bacteria were isolated from a blood culture, antimicrobial therapy was adjusted according to the antibiotic resistance patterns obtained. Detailed information on patients was collected from computer databases. These data included age, sex, malignant disease classification, presence of indwelling catheter, neutrophil counts, prior antibiotic usage, and clinical outcome. Information on isolated strains, including etiology and susceptibility to antibiotics, was obtained from a microbiology laboratory computer database.
Microbiology
In our unit, blood culture tests are conducted for all patients with febrile neutropenia. An automated blood culture system (BACTEC) was used for each test. Several samples were obtained from the same patient and treated as independent results. Antibiotic susceptibilities were determined by the breakpoints standardized by the Clinical and Laboratory Standards Institute (CLSI; formerly the NCCLS). 16 The screening and confirmation tests for ESBL and metallo-b-lactamase were conducted according to the recommendations of the CLSI. 16 In addition, b-lactamase producers were confirmed using a Cica b test I/MBL kit (Kanto Chemical Co. Ltd, Tokyo, Japan). Strains that were positive for ESBL based on the confirmation tests were then evaluated for genotype. The genotyping of metallo-b-lactamase was conducted when the screening test was positive. PCR was conducted using five sets of primers to amplify type-specific ESBL genes, including CTX-M, TEM, and SHV types. 17 Three sets of primers were used to detect group-specific CTX-M b-lactamase genes, and then the different types of CTX-M were determined by DNA sequencing. 17 PCR was conducted using primers specific for metallo-b-lactamase genes.
Statistical analysis
For the basic characteristics of patients with cefepime-resistant isolates and patients with cefepime-sensitive isolates, categorical variables were analyzed using a two-tailed Chi-square test, and continuous variables were compared using the Mann-Whitney Utest. Odds ratios and 95% confidence intervals were calculated to compare resistance patterns to various antibiotics between cefepime-resistant and cefepime-sensitive isolates. A value of p < 0.05 was considered to be statistically significant. All statistical calculations were performed using SAS software (SAS Institute, Inc., Cary, NC, USA).
Results
Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients
A total of 142 bacteria were recovered from blood cultures associated with 798 febrile episodes in patients with hematological malignancies (Table 1) . Among febrile episodes with bacteremia, 132 were caused by a single strain and five by two strains. The incidence of Gram-positive isolates was approximately 50%, with coagulase-negative staphylococci (CoNS) being predominant. Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) were not detected among the Gram-positive isolates. Among the isolates, 68 (47.9%) were Gram-negative organisms, of which E. coli (18.3%), P. aeruginosa (14.8%), and K. pneumoniae (9.2%) accounted for the majority. We focused on Gram-negative isolates rather than Gram-positive ones, because CoNS, which were predominant among Gram-positive isolates, indicated the possibility of contaminated samples; the majority of the Gram-positive isolates were fully sensitive to vancomycin, which is added when isolating Gram-positive strains. The prevalence of Gram-negative isolates resistant to cefepime, an antibiotic agent adopted at our institution as an initial therapy for febrile neutropenia, was examined because a high rate of resistance to cefepime affects the choice of empirical antibiotics for febrile neutropenia. Table 2 shows the number of cefepimeresistant Gram-negative strains isolated from febrile neutropenic patients in each year of this study. Cefepime-resistant isolates comprised 24 (35.3%) of 68 Gram-negative isolates analyzed, and had significantly increased in 2007. About half of the isolates of E. coli and P. aeruginosa showed resistance to cefepime, and approximately 20% of K. pneumoniae were resistant to cefepime.
Phenotypic and molecular characterization of cefepime-resistant Gram-negative strains
The cefepime-resistant Gram-negative isolates were then characterized with respect to production of b-lactamase enzymes. Screening of strains producing ESBL and metallo-blactamase was conducted. Four P. aeruginosa isolates were suspected to be metallo-b-lactamase producers, but no strains were confirmed as metallo-b-lactamase producers using PCR methods. All cefepime-resistant E. coli and K. pneumoniae strains were phenotypically identified as ESBL-producing isolates by the clavulanate test, and all were confirmed as isolates containing ESBL genes at a molecular level. Table 3 shows the ESBL genotypes of all cefepime-resistant E. coli and K. pneumoniae strains. Twelve cefepime-resistant E. coli isolates were classified as the following four types: CTX-M-14 alone, a combination of CTX-M-14 and CTX-M-2, a combination of CTX-M-14 and TEM, and TEM alone. Two K. pneumoniae strains resistant to cefepime produced CTX-M-14 and SHV b-lactamase. Although there is concern over the spread of a particular ESBL strain through nosocomial outbreaks, the detection of different ESBL genotypes indicates that these ESBLproducing strains did not disseminate from a single strain with a certain genotype. Table 4 shows the resistance rates to different antibiotics of cefepime-resistant, ESBL-producing, and cefepime-sensitive isolates. Most of the cefepime-resistant and ESBL-producing isolates were resistant to all generations of cephalosporins, and this resistance pattern was significantly different to that of cefepimesensitive isolates. Most cefepime-resistant isolates were resistant to various fourth-generation cephalosporins, such as cefozopran and cefpirome. In contrast, most cefepime-resistant isolates retained favorable susceptibility to carbapenems, and only approximately 10% of cefepime-resistant isolates were resistant to meropenem. All ESBL-producing isolates were sensitive to carbapenems. Most of the cefepime-resistant and ESBL-producing isolates were susceptible to aminoglycosides.
Antimicrobial susceptibilities of cefepime-resistant Gramnegative strains
Serial blood cultures were acquired for 20 of 24 patients (83.3%) with cefepime-resistant, 12 of 14 patients (85.7%) with ESBLproducing, and 39 of 44 patients (88.6%) with cefepime-sensitive bacteremia. The detected bacteria were eliminated after antibiotic treatment in all of the groups. In the control patients with cefepime-sensitive bacteremia, no patients died of infection during antibiotic therapy. In case patients with cefepime-resistant bacteremia, one patient died during treatment, due to possible septic shock caused by P. aeruginosa. This P. aeruginosa isolate was resistant to carbapenems, including imipenem/cilastatin and meropenem. There were no mortalities among patients with ESBL-producing bacteremia during antimicrobial therapy.
Discussion
The present study results indicate an increase in cefepimeresistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies under the therapeutic strategy of cefepime usage as an initial antibiotic treatment. Cefepime-resistant isolates consisted of P. aeruginosa, E. coli, and K. pneumoniae. None of the P. aeruginosa strains produced metallo-blactamase, while all of the E. coli and K. pneumoniae strains were ESBL producers. Furthermore, genotyping of the ESBL enzymes indicated the predominance of the CTX-M type. To our knowledge, no previous reports have described the molecular analysis of blactamase in the field of bacteremia recovered from febrile neutropenic patients. These data give rise to practical suggestions for surveillance and therapeutic strategies.
The present study indicated that CTX-M enzymes are most prevalent in ESBL-producing strains isolated from febrile neutropenic bacteremia. Recent surveillance tests have reported that organisms producing CTX-M b-lactamase, a new ESBL type, have been replacing those that produce TEM and SHV enzymes, the original ESBL types. 18, 19 CTX-M-producing bacteria acquire resistance to all generations of cephalosporins, while remaining highly susceptible to carbapenems. 19 The present data are consistent with this resistance pattern of organisms with CTX-M ESBL enzymes. As a characteristic of the CTX-M type, CTX-M-producing bacteria not Klebsiella pneumoniae CTX-M-14 SHV only cause nosocomial infections, but also acquire the potential for spreading throughout community environments. 19 Also, it should be considered that CTX-M ESBL-producing organisms could be imported from a community site. To identify community-onset nosocomial infections induced by CTX-M-producing organisms, surveillance for ESBL genotyping and cloning is needed in all units, not just hematology units. It would be reasonable to assume that Gram-negative bacteremia caused by febrile neutropenia could induce fatal infections, and that failure of an initial treatment for multidrug-resistant bacteremia might lead to a high mortality. However, in the present study, only one patient died during treatment of Gram-negative bacteremia, both cefepime-sensitive and cefepime-resistant. In most cases of patients with cefepime-resistant isolates, rapid bacterial detection and prompt antibiotic change resulted in successful treatment. All of the secondary antibiotics, except in two cases, were meropenem, and this treatment success clinically reinforces the finding that approximately 90% of the cefepimeresistant strains, including ESBL-producers, were sensitive to meropenem. The clinical outcome of infections caused by ESBLproducing organisms remains controversial, because no prospective studies have been conducted to assess prognosis in a statistically significant number of patients. 9 All observations, including the present data, have been obtained from case-control studies with relatively small numbers of patients. 9 A new study should be designed to specifically resolve this clinical question. Our unit has faced an increase in bacteremia resistant to cefepime, which has been used as an initial antibiotic agent for febrile neutropenia, while carbapenems, especially meropenem, retain high activity against cefepime-resistant bacteremia. Although it appears reasonable to choose carbapenems as the initial antimicrobial treatment for patients with febrile neutropenia, this treatment would be adopted only in the case of our patients. The use of high doses of carbapenems may result in the emergence of multidrug-resistant P. aeruginosa strains, which have been less frequently detected in our unit. In recent years, many comparative studies have recommended carbapenems and b-lactam/b-lactamase inhibitor combinations, particularly piperacillin-tazobactam, as an initial therapy for febrile neutropenia. 5, 6 Rotation of antibiotics has been suggested as a strategy to control the resistance of microorganisms to antibiotic treatments. Bacteria that are resistant to one class of antibiotics would be eliminated by another class of antibiotics, which results in their growth inhibition. For febrile neutropenic patients, our unit has instituted rotation of the primary antimicrobial, including cefepime, meropenem, and piperacillin-tazobactam. The primary purpose is to evaluate whether rotation of antibiotics affects the susceptibility patterns of multidrug-resistant bacteremia in febrile neutropenic patients.
One concern is that failure of the first antibiotic therapy for febrile neutropenic patients may influence mortality. The present data reinforce the need for continuous surveillance, including etiology and resistance patterns; this is indispensable in choosing appropriate antibiotics for febrile neutropenic bacteremia. Moreover, the present study identified a high prevalence of multidrugresistant organisms with CTX-M ESBL types, which are currently on the increase worldwide. Identification of the genotypes of blactamase-producing organisms provides valuable information on antibiotic resistance patterns.
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